[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369729-105":59,"doc-detail-369729-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tumor-associated-neutrophil-precursors-impair-homologous-dna-repair-and-promote-sensitivity-to-parp-inhibition","Tumor-associated neutrophil precursors impair homologous DNA repair and promote sensitivity to PARP inhibition","","Tumor evolution drives therapy-resistant, aggressive cancer clones, and the tumor microenvironment may shape this process through immune mechanisms. The study identifies tumor-associated neutrophil precursors (PreNeu) enriched in highly proliferative hormone-dependent breast cancers that impair DNA repair capacity. Mechanistically, succinate secreted by PreNeu inhibits homologous recombination, fostering PARP-1–regulated error-prone non-homologous end joining. PARP pathway inhibition increases tumor killing, correlating PreNeu scores with patient copy-number alterations and synergizing with endocrine therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumor-associated-neutrophil-precursors-impair-homologous-dna-repair-and-promote-sensitivity-to-parp-inhibition/369729/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumor-associated-neutrophil-precursors-impair-homologous-dna-repair-and-promote-sensitivity-to-parp-inhibition/369729.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are tumor-associated neutrophil precursors (PreNeu) in this study?","Question",{"text":112,"@type":113},"PreNeu are a subset of tumor-associated neutrophils identified in hormone-dependent breast cancers. They are enriched in highly proliferative tumors and impair DNA repair capacity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do PreNeu affect DNA repair and PARP inhibitor sensitivity?",{"text":117,"@type":113},"Succinate secreted by PreNeu inhibits homologous recombination, promoting PARP-1–regulated non-homologous end joining that leads to error-prone repair. This increases genomic instability and sensitivity to PARP inhibition.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic effects result from inhibiting the implicated pathways?",{"text":121,"@type":113},"Selective inhibition increases tumor cell killing both in vitro and in vivo. The PreNeu-associated pro-tumoral effect is counteracted by PARP-1 inhibitors and shows synergy with endocrine therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369729,1790908053,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Article [https://doi.org/10.1038/s41467-025-61422-9](https://doi.org/10.1038/s41467-025-61422-9)  \nTumor-associated neutrophil precursors impair homologous DNA repair and promote sensitivity to PARP inhibition  \nReceived: 15 May 2024  \n\n| Accepted: 23 June 2025 |\n| --- |\n| |\n| Check for updates |\n\nSiddhartha Mukherjee1,2,16, Cindy Garda 1,2,16, Letizia Boffa 1,2,16,  \nAngela Rita Elia1,2,16, Matteo Massara 1,2, Maria Teresa Balia1,2, Daniela Brina1,2, Simone Mosole1,2, Anna Campagnari1,2, Giada Andrea Cassanmagnago 1,3, Andrea Rinaldi1,2, Giacomo Lazzaroni1,2, David Jarrossay4, Diego Morone 4, Ilaria Ceppi 4, Riccardo De Sillo1,2, Isabella Giacomini1,2, Ilaria Craparotta3, Laura Di Rito1,2, Simon Barry 5, Endre Laczko6, Sebastian Streb 6, Francesco Meani7,8, Simona Di Lascio8, Nancy Hynes 9, Enrico Lugli 10, Simone Puccio 10,11, Stephen-John Sammut12, Ulrike Perriard13, Yves Harder2,14, Lorenzo Rossi8, Maria Luisa Gasparri7, Marco Bolis 1,3,15, Petr Cejka 4 & Arianna Calcinotto 1,2   \nTumor evolution is one of the major mechanisms responsible for acquiring therapy-resistant and more aggressive cancer clones. Whether the tumor microenvironment through immune-mediated mechanisms might promote the development of more aggressive cancer types is crucial for the identiﬁcation of additional therapeutic opportunities. Here, we identify a subset of tumor-associated neutrophils, deﬁned as tumor-associated neutrophil precursors (PreNeu). These PreNeu are enriched in highly proliferative hormonedependent breast cancers and impair DNA repair capacity. Mechanistically, succinate secreted by tumor-associated PreNeu inhibits homologous recombination, promoting error-prone DNA repair through non-homologous endjoining regulated by PARP-1. Consequently, breast cancer cells acquire genomic instability promoting tumor editing and progression. Selective inhibition of these pathways induces increased tumor cell killing in vitro and in vivo. Tumor-associated PreNeu score correlates with copy number alterations in highly proliferative hormone-dependent tumors from breast cancer patients. Treatment with PARP-1 inhibitors counteract the pro-tumoral effect of these neutrophils and synergize with endocrine therapy.  \nHormone-dependent breast cancers, also referred to as estrogen receptor-positive (ER+) or luminal-like tumors, rely on estrogens to promote proliferation and inhibit apoptosis1. Highly proliferative subtype of ER+ breast cancer, associated with Luminal B tumors2, has greater tumor aggressiveness and signiﬁcantly worse prognoses than low proliferative Luminal A tumors3. Since ERα is the primary  \noncogenic driver in most ER+ breast cancers, endocrine-based therapeutic options are the current standard of care3. Although endocrine therapies extend overall survival, one-third of all early-stage ER+ breast cancer patients experience treatment resistance, leading to metastasis4–6. Genomic alterations in early and advanced breast cancers are proposed to be the cause of emergent therapy-resistant  \nA full list of afﬁliations appears at the end of the paper. e-mail: [arianna.calcinotto@ior.usi.ch](arianna.calcinotto@ior.usi.ch)  \ncancer clones7. The well-established dependency of cancer cells on the tumor microenvironment (TME) suggests that the microenvironment might have a role in the development of more aggressive cancer types. ER+ breast cancers are considered to be immunologically cold due to low inﬁltration of lymphocytes within the TME8. A growing body of evidence suggests that the TME of ER+ breast cancer is highly inﬁltrated by neutrophils and estrogen signaling contributes to the immunosuppressive nature of breast cancer by driving the recruitment and function of these cells9–11. Lectin-type oxidized LDL receptor- 1 (LOX-1) expression, which has been associated with higher immunosuppressive activity, deﬁnes tumor-inﬁltrated immunosuppressive neutrophils12,13.  \nOur laboratory and others have previously demonstrated different pathogenic funct","cbCaiiFwJOwh4WMi","https://ap.wps.com/l/cbCaiiFwJOwh4WMi","pdf",4038895,"English","# Abstract\n## Background and rationale\n## PreNeu identification in breast cancer\n## Mechanistic link to DNA repair and PARP-1\n## Therapeutic implications and synergy","[{\"question\":\"What are tumor-associated neutrophil precursors (PreNeu) in this study?\",\"answer\":\"PreNeu are a subset of tumor-associated neutrophils identified in hormone-dependent breast cancers. They are enriched in highly proliferative tumors and impair DNA repair capacity.\"},{\"question\":\"How do PreNeu affect DNA repair and PARP inhibitor sensitivity?\",\"answer\":\"Succinate secreted by PreNeu inhibits homologous recombination, promoting PARP-1–regulated non-homologous end joining that leads to error-prone repair. This increases genomic instability and sensitivity to PARP inhibition.\"},{\"question\":\"What therapeutic effects result from inhibiting the implicated pathways?\",\"answer\":\"Selective inhibition increases tumor cell killing both in vitro and in vivo. The PreNeu-associated pro-tumoral effect is counteracted by PARP-1 inhibitors and shows synergy with endocrine therapy.\"}]","Tumor-associated neutrophil precursors impair homologous DNA repair and promote sensitivity to PARP inhibition | PDF",1790184249,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfc5be2367f134e8b3f7bc6c2211d59d.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b04567e32e82917e08749830bb8210a.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a97290e18cc9505a0bce29c7d081db07.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d39dc10d9b1d528b4dea928ee724b663.webp",980,1301]